CN110857444A - Preparation method of scyllo-inositol - Google Patents
Preparation method of scyllo-inositol Download PDFInfo
- Publication number
- CN110857444A CN110857444A CN201810973696.4A CN201810973696A CN110857444A CN 110857444 A CN110857444 A CN 110857444A CN 201810973696 A CN201810973696 A CN 201810973696A CN 110857444 A CN110857444 A CN 110857444A
- Authority
- CN
- China
- Prior art keywords
- inositol
- scyllo
- thermotolerant
- promoter
- dehydrogenase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01018—Inositol 2-dehydrogenase (1.1.1.18)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a method for preparing scyllo-inositol by catalyzing myoinositol with whole cells of microorganisms and/or lysate thereof, which comprises the steps of constructing engineering bacteria for expressing thermotolerant myoinositol dehydrogenase and/or thermotolerant scyllo-inositol dehydrogenase genes, carrying out cell membrane permeability treatment and/or disruption on the engineering bacteria, and then converting the myoinositol into the scyllo-inositol by utilizing the permeable engineering bacteria or the lysate thereof. Compared with the existing method for producing scyllo-inositol, the method of the invention has the advantages of simple production process, low production cost, high yield and the like.
Description
Technical Field
The invention relates to the technical field of biological engineering, in particular to a preparation method of scyllo-inositol, and specifically relates to a method for converting scyllo-inositol into myo-inositol by catalyzing myo-inositol with whole cells of microorganisms and/or lysis solution thereof.
Background
Scyllo-inositol (SI) is a differential isomer of myo-inositol (MI) (FIG. 1), exists in plants, animals and some bacteria, but its content in nature is much lower than that of myo-inositol.Studies show that scyllo-inositol has amyloid β protein aggregation inhibition, can regulate central nerve signals dependent on myo-inositol, is a potential drug for treating Alzheimer's disease, and has been clinically tested by Transition Therapeutics Ireland Limited, and can improve cognitive level in people with Down syndrome.
In the traditional synthetic method, scyllo-inositol is mainly synthesized by taking myo-inositol as a raw material through complicated steps and adopting a chemical method, but the method needs protection and deprotection of hydroxyl, has complicated steps and is not beneficial to large-scale production. In recent years, with the development of biotechnology, the biological production of scyllo-inositol has become a new trend. It has been reported that a Cell factory of Bacillus subtilis (Bacillus subtilis) is used to produce scyllo-inositol (Yamaoka M, Osawa S, Morinaga T, Takenaka S, Yoshida K-i (2011) A Cell factory of Bacillus subtilis for the simple biochemical conversion of myo-inositol derivative microorganism Cell factory 10; Tanaka K, Tajima S, Takenaka S, Yoshida K-i (2013) enhanced Bacillus subtilis Cell factory for producing bacterial-inositol derivative, Bacillus subtilis Cell factory for producing Bacillus strain-inositol derivative, Bacillus strain culture Cell 331, Bacillus strain culture Cell factory for producing Bacillus strain-inositol derivative, Bacillus strain for producing Bacillus strain, Bacillus strain for producing Cell, Bacillus strain for producing strain, Bacillus strain for strain, Bacillus strain for producing strain, Bacillus strain, Cell strain, Bacillus strain K-strain for producing strain, Cell strain, Bacillus strain, Cell strain, Aspergillus strain, Cell strain, strain. This method requires a complicated metabolic flow control, and the yield of scyllo-inositol depends on the nutrient of the medium, which undoubtedly increases the complexity of the process.
Therefore, it is desired to develop a novel method for producing scyllo-inositol with a simple production process, a high yield and a low cost.
Disclosure of Invention
Aiming at the problems of the existing method for preparing scyllo-inositol, the invention provides a method for producing scyllo-inositol by catalyzing myo-inositol dehydrogenase (EC 1.1.1.18, IDH) and scyllo-inositol dehydrogenase (EC 1.1.1.370, SIDH) by using whole cells expressing the myo-inositol dehydrogenase (EC 1.1.1.18) and the scyllo-inositol dehydrogenase (EC 1.1.1.370, SIDH) and/or a lysate thereof. The method has the advantages of simple production process, low production cost, high yield and the like.
In order to solve the technical problems, the invention adopts the following technical scheme:
according to one aspect of the present invention, the present invention relates to a method for producing scyllo-inositol, comprising the steps of:
(1) constructing engineering bacteria for co-expressing thermotolerant myo-inositol dehydrogenase and thermotolerant scyllo-inositol dehydrogenase and/or engineering bacteria for respectively expressing the thermotolerant myo-inositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase;
(2) fermenting the engineering bacteria constructed in the step (1) to obtain whole cells;
(3) performing cell membrane permeability treatment and/or disruption on the whole cells obtained in the step (2) to obtain permeable whole cells and/or lysate;
(4) utilizing the whole cell obtained in step (3) to co-express a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a mixture of whole cells expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a lysate of whole cells co-expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a mixture of a lysate of whole cells expressing a thermomycent myo-inositol dehydrogenase and a lysate of whole cells expressing a thermovent scyllo-inositol dehydrogenase, and/or a mixed lysate of whole cells co-expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a lysate of whole cells expressing a thermomycent myo-inositol dehydrogenase and a lysate of whole cells expressing a thermovent scyllo-inositol dehydrogenase The compounds catalyze myo-inositol to produce scyllo-inositol.
According to the invention, the catalytic pathway comprises: from thermostable myo-inositol dehydrogenase in NAD+Oxidizing a substrate myo-inositol to an intermediate myo-inositol monoketone in the presence of a catalyst; the intermediate myoinositol monoketone is reduced to the product scyllo-inositol by a thermostable scyllo-inositol dehydrogenase in the presence of NADH, as shown in FIG. 2. In bookIn the catalytic pathway of the invention, the desired NAD+From the engineered bacterial cells, i.e., the method of the invention does not comprise additional NAD addition+The step (2).
Preferably, according to the present invention, in step (1), the engineered bacterium comprises a vector co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase, or comprises both a vector expressing a thermotolerant myo-inositol dehydrogenase and a vector expressing a thermotolerant scyllo-inositol dehydrogenase, or comprises a vector expressing a thermotolerant myo-inositol dehydrogenase, or comprises a vector expressing a thermotolerant scyllo-inositol dehydrogenase. As will be understood by those skilled in the art, the vectors and engineered bacteria of the present invention can be prepared by conventional methods known in the art, for example, by constructing by recombinant DNA techniques to obtain the gene iolG encoding myo-inositol dehydrogenase and the gene iolX encoding scyllo-inositol dehydrogenase, constructing recombinant expression vectors, and transferring into host bacteria to obtain genetically engineered bacteria.
Preferably, according to the present invention, in step (1), "thermostable myo-inositol dehydrogenase" refers to an enzyme having a function of oxidizing myo-inositol to myo-inositol monoketone at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher.
Further preferably, the thermotolerant myoinositol dehydrogenase is derived from a thermophilic microorganism, such as Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Thermotoga maritima (Thermotoga maritima), Pseudothermoga thermophilum, and the like; or the amino acid sequence of said thermotolerant myo-inositol dehydrogenase has at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identity to a thermotolerant myo-inositol dehydrogenase derived from said thermophilic microorganism.
More preferably, the thermotolerant myo-inositol dehydrogenase is derived from Geobacillus kaustophilus; or the amino acid sequence of said thermotolerant myo-inositol dehydrogenase has at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identity to a thermotolerant myo-inositol dehydrogenase derived from Geobacillus kaustophilus.
Preferably, according to the present invention, in step (1), "thermostable scyllo-inositol dehydrogenase" refers to an enzyme having a function of reducing myoinositol monoketone to scyllo-inositol at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher.
Further preferably, the thermostable scyllo-inositol dehydrogenase is derived from a thermophilic microorganism, such as Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Geobacillus thermoeovorans, Thermotoga maritima (Thermotogaritia) and the like; or the amino acid sequence of the thermostable scyllo-inositol dehydrogenase has at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identity with the thermostable scyllo-inositol dehydrogenase derived from the thermophilic microorganism.
More preferably, the thermostable scyllo-inositol dehydrogenase is derived from Geobacillus kaustophilus; or the amino acid sequence of the thermostable scyllo-inositol dehydrogenase has at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identity with a thermostable scyllo-inositol dehydrogenase derived from Geobacillus kaustophilus.
Preferably, according to the present invention, the vector co-expressing the thermotolerant myoinositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase includes a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant scyllo-inositol dehydrogenase gene, and a second terminator, or includes a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant myoinositol dehydrogenase gene, and a second terminator, or includes a promoter, a thermotolerant scyllo-inositol dehydrogenase gene, a thermotolerant myoinositol dehydrogenase gene, a terminator; the vector for expressing the heat-resistant myoinositol dehydrogenase comprises a promoter, a heat-resistant myoinositol dehydrogenase gene and a terminator; the carrier for expressing the heat-resistant scyllo-inositol dehydrogenase comprises a promoter, a heat-resistant scyllo-inositol dehydrogenase gene and a terminator.
It will be appreciated by those skilled in the art that a variety of expression vectors known in the art may be used in the present invention, including, but not limited to, the pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, and the like. Preferably, the vector is pETDuet-1, pET-29a (+).
It will be appreciated by those skilled in the art that a variety of host bacteria known in the art may be used in the present invention, including but not limited to E.coli, Pichia, Saccharomyces cerevisiae, Bacillus subtilis, and the like. Preferably, the host bacterium is escherichia coli BL21(DE 3).
One skilled in the art will appreciate that various promoters known in the art may be used as the promoter, first promoter, and/or second promoter of the present invention, including but not limited to the T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, and the like. Preferably, the promoter, the first promoter and the second promoter are independent of each other, and are T7 promoters.
One skilled in the art will appreciate that various terminators known in the art can be used as the terminator, first terminator, and/or second terminator of the present invention, including but not limited to the T7 terminator, the rrnB T1 terminator, the rrnB T2 terminator, and the like. Preferably, the terminator, the first terminator and the second terminator are independent of each other a T7 terminator.
According to the present invention, in step (2), the preparation of the whole cells is performed using a method known in the art. The fermentation may use any medium suitable for the expression of the foreign protein, including, but not limited to, LB medium, TB medium, and the like.
According to the present invention, in step (3), the cell membrane permeability treatment includes, but is not limited to, heat treatment, addition of an organic solvent and/or addition of a surfactant, and the like. Preferably, the cell membrane permeability treatment is a heat treatment. The purpose of the permeability treatment of the cell membrane is to allow the entry of extracellular myoinositol into the cell through the cell membrane.
Preferably, the heat treatment temperature is 45-95 ℃; further preferably, the heat treatment temperature is 55-90 ℃; more preferably, the heat treatment temperature is 60-80 ℃; most preferably, the heat treatment temperature is 70 ℃.
Preferably, the heat treatment time is 1-40 min; further preferably, the heat treatment time is 5-30 min; more preferably, the heat treatment time is 10-25 min; most preferably, the heat treatment time is 20 min.
Preferably, the cell concentration at the time of heat treatment is OD60010-300; further preferably, the cell concentration is OD60020-200; more preferably, the cell concentration is OD60050-150; most preferably, the cell concentration is OD600＝100。
According to the invention, the heat treatment can be carried out in a buffer-free system or in a buffer system; preferably, the heat treatment is performed in a buffer system, which may be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, or the like. Among them, phosphate buffer solutions such as sodium phosphate buffer solution, potassium phosphate buffer solution, and the like.
According to the present invention, in step (3), the cell disruption is performed using a method known in the art. Cell disruption methods include, but are not limited to, sonication, high pressure homogenization, and the like.
Preferably, in the reaction system for preparing scyllo-inositol by catalyzing myoinositol with permeable whole cells or a mixture of permeable whole cells according to the present invention, in step (4), the concentration of myoinositol as a substrate is 1-400g/L, and the amount of myoinositol added to the permeable whole cells or the mixture of permeable whole cells is OD6001-100; more preferably, the concentration of myoinositol as substrate is 100-350g/L and the amount of permeable whole cells or mixture of permeable whole cells added is OD60010-50; most preferably, the substrate myoinositol is present at a concentration of 250g/L and the permeable whole cells or mixture of permeable whole cells are added in an amount OD600＝20-40。
Preferably, according to the present invention, in step (4), the reaction conditions for catalyzing myoinositol with permeable whole cells or a mixture of permeable whole cells to produce scyllo-inositol are as follows: reacting at pH 6.0-8.0 and 50-80 deg.C for 0.5-72 hr; more preferably at pH 6.5-7.5, at 55-75 deg.C for 3-48 h; most preferably at a pH of 7.0 at 60-65 ℃ for 6-24 h.
According to the invention, the reaction catalyzed by permeable whole cells or a mixture of permeable whole cells can be carried out in a buffer-free system or a buffer system; preferably, the catalytic reaction is performed in a buffer system using permeable whole cells or a mixture of permeable whole cells, and the buffer may be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, or the like. Among them, phosphate buffer solutions such as sodium phosphate buffer solution, potassium phosphate buffer solution, and the like.
Preferably, in the reaction system for preparing scyllo-inositol by catalyzing myoinositol with cell lysate or mixture of cell lysates in step (4), the concentration of myoinositol as substrate is 1-400g/L, and the cell lysate or mixture of cell lysates is whole-cell OD600The adding amount of the cracking solution is 5 to 95 percent of the total volume of the reaction solution when the reaction solution is 10 to 100 percent; more preferably, the concentration of myoinositol as substrate is 100-300g/L and the cell lysate or mixture of cell lysates is the whole cell OD600The adding amount of the cracking solution is 50 to 90 percent of the total volume of the reaction solution when the reaction solution is 40 to 150 hours; most preferably, the concentration of myoinositol as substrate is 250g/L and the cell lysate or mixture of cell lysates is whole cell OD600The amount of the lysate added was 90% of the total volume of the reaction solution, when the amount of the lysate was 100%.
Preferably, according to the present invention, in step (4), the reaction conditions for catalyzing the production of scyllo-inositol from myoinositol using a cell lysate or a mixture of cell lysates are as follows: reacting at pH 6.0-8.0 and 50-80 deg.C for 0.5-72 hr; more preferably at pH 6.5-7.5, at 55-75 deg.C for 3-48 h; most preferably at a pH of 7.0 at 60-65 ℃ for 6-24 h.
According to the invention, the catalytic reaction by using the cell lysate or the mixture of the cell lysate can be carried out in a buffer-free system or a buffer system; preferably, the catalytic reaction is performed in a buffer system by using cell lysate or a mixture of cell lysates, and the buffer can be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer and the like. Among them, phosphate buffer solutions such as sodium phosphate buffer solution, potassium phosphate buffer solution, and the like.
Preferably, according to the present invention, in step (4), the ratio of permeable whole cells expressing a thermotolerant myo-inositol dehydrogenase to permeable whole cells expressing a thermotolerant scyllo-inositol dehydrogenase in the mixture of permeable whole cells is 0.1:1 to 10: 1; more preferably from 0.5:1 to 5: 1; most preferably 1: 1; the ratio of whole cells used by the whole cell lysate expressing the thermostable myo-inositol dehydrogenase to whole cells used by the whole cell lysate expressing the thermostable scyllo-inositol dehydrogenase in the mixture of the whole cell lysates is 0.1:1-10: 1; more preferably from 0.5:1 to 5: 1; most preferably 1: 1.
According to the invention, the scyllo-inositol can also be prepared by catalyzing myo-inositol with a mixture of permeable whole cells and cell lysate under the following reaction conditions: reacting at pH 6.0-8.0 and 50-80 deg.C for 0.5-72 hr; more preferably at pH 6.5-7.5, at 55-75 deg.C for 3-48 h; most preferably at a pH of 7.0 at 60-65 ℃ for 6-24 h.
According to another aspect of the present invention, the present invention relates to the above-mentioned vector for co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase, the vector for expressing a thermotolerant myo-inositol dehydrogenase, and the vector for expressing a thermotolerant scyllo-inositol dehydrogenase.
According to another aspect of the invention, the invention relates to the engineering bacteria for co-expressing the thermotolerant myo-inositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase, the engineering bacteria for expressing the thermotolerant myo-inositol dehydrogenase and the engineering bacteria for expressing the thermotolerant scyllo-inositol dehydrogenase. According to the invention, the engineering bacteria for coexpressing the thermotolerant myo-inositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase comprise a carrier for coexpressing the thermotolerant myo-inositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase, or comprise a carrier for expressing the thermotolerant myo-inositol dehydrogenase and a carrier for expressing the thermotolerant scyllo-inositol dehydrogenase; the engineering bacteria for expressing the thermotolerant myoinositol dehydrogenase comprise a vector for expressing the thermotolerant myoinositol dehydrogenase; the engineering bacteria for expressing the heat-resistant scyllo-inositol dehydrogenase comprise a carrier for expressing the heat-resistant scyllo-inositol dehydrogenase.
Compared with the prior art, the invention has the following beneficial effects:
(1) the invention utilizes the whole cells expressing the heat-resistant myo-inositol dehydrogenase and the heat-resistant scyllo-inositol dehydrogenase and/or the lysate thereof to catalyze myo-inositol to produce scyllo-inositol, and develops a novel method which is simple and easy to prepare scyllo-inositol in a large scale.
(2) The inventionNo need of additional NAD in the reaction system+Can realize NAD+The self-circulation of NADH is beneficial to reducing the production cost, and has important industrial application value.
(3) The preparation of scyllo-inositol in the method can be carried out at higher temperature, so that the solubility of substrate myo-inositol can be increased.
(4) The invention adopts the whole cells expressing the heat-resistant myo-inositol dehydrogenase and the heat-resistant scyllo-inositol dehydrogenase as the catalyst, and only needs heat treatment to change the permeability of cell membranes, thereby being beneficial to simplifying the production process and improving the safety of products.
(5) The conversion reaction of the scyllo-inositol in the method can be carried out in a buffer-free system or a buffer system, and a culture medium containing a carbon source, a nitrogen source, inorganic salts and antibiotics is not needed, so that the method is favorable for reducing the production cost on one hand and is favorable for separating and purifying the scyllo-inositol product on the other hand.
Drawings
FIG. 1 shows the chemical structures of scyllo-inositol and myo-inositol.
FIG. 2 is a schematic diagram of the production of scyllo-inositol from myoinositol catalyzed by permeable whole cells and/or lysates according to the invention. MI: myo-inositol; and (3) SI: scyllo-inositol; IDH: myo-inositol dehydrogenase; and (3) SIDH: scyllo-inositol dehydrogenase.
FIGS. 3A-C are maps of recombinant expression vectors pETDuet-iolG, pET29a-iolX, and pETDuet-iolG-iolX, respectively.
FIG. 4 is an HPLC chromatogram of myoinositol and scyllo-inositol.
FIG. 5 shows the preparation of scyllo-inositol from whole cells heat-treated under different conditions.
FIG. 6 shows the preparation of scyllo-inositol at different reaction temperatures.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following embodiments are provided to further illustrate the technical solutions of the present invention. It is to be understood that the described embodiments are exemplary only and are not limiting upon the scope of the invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be within the scope of the invention.
EXAMPLE 1 cloning of the iolG and iolX genes
The thermotolerant myo-inositol dehydrogenase in this example is from Geobacillus kaustophilus, NCBI accession number WP _ 011231389; thermostable scyllo-inositol dehydrogenase is also from Geobacillus kaustophilus, NCBI accession No. WP _ 011231387.1. Geobacillus kaustophilus is purchased from China general microbiological culture Collection center (CGMCC). These two genes were obtained by PCR from genomic DNA using different primers, respectively: geobacillus kaustophilus was inoculated into 5mL of a liquid nutrient broth agar medium (peptone 10g/L, beef extract 3g/L, NaCl5g/L, adjusted to pH7.0 with NaOH), cultured at 55 ℃ until logarithmic growth phase, and the genome was extracted using a DNA Kit (Tiangen Biochemical technology Co., Ltd., China). Primer iolG-F (containing BamHI cleavage site) was used: 5'-CGCGGATCCGATGACTCGGGTGAAAGTAGG-3' and iolG-R (containing SalI cleavage sites): 5'-ACGCGTCGACTTATTTTGACGGAGCTGTTTG-3' amplifying the iolG gene; primer iolX-F (containing NdeI cleavage site): 5'-GGAATTCCATATGACCGTTCGTTGTGCAG-3' and iolX-R (containing KpnI cleavage site): 5'-GGGGTACCCTAGCGTGTTTGCTCAGCTAC-3' the iolX gene was amplified.
All primers were synthesized by Suzhou Jinweizhi Biotechnology, Inc. The PCR conditions of the gene are 94 ℃ denaturation for 5min, and the cycle is 30 times according to the following parameters: denaturation at 94 ℃ for 15s, annealing at 58 ℃ for 15s, extension at 72 ℃ for 1min, and final extension at 72 ℃ for 10 min. The products obtained from the PCR reaction were analyzed by 0.8% agarose gel electrophoresis, respectively. After confirming that the size of the fragment is correct by imaging of a gel imaging system, a DNA purification recovery kit (Tiangen Biochemical technology Co., Ltd., China) is adopted to recover the target fragment for constructing the recombinant expression vector.
Example 2 construction of recombinant engineering bacteria
(1) Construction of pETDuet-iolG
The pETDuet-1 plasmid and the iolG gene containing two cleavage sites obtained in example 1 by PCR were cleaved with BamHI/SalI double enzyme at 37 ℃ respectively, and the double-cleaved objective fragment and the expression vector were recovered separately and ligated at 22 ℃ for 5 hours under the action of T4 ligase. Transforming the ligation product into competent E.coli Top10 by calcium chloride method, selecting transformants for colony PCR and double enzyme digestion identification, selecting 2-3 positive transformants for further verification by sequencing, and displaying the sequencing result to successfully obtain pETDuet-iolG recombinant vector.
The plasmid map of pETDuet-iolG is shown in FIG. 3A.
(2) Construction of pET29a-iolX
Separately digesting the pET-29a (+) plasmid and the iolX gene containing two digestion sites obtained by PCR in example 1 at 37 ℃ with NdeI/KpnI double enzyme, the target fragment and the expression vector which had been digested by double digestion were recovered separately, and ligated at 22 ℃ for 5 hours under the action of T4 ligase. Transforming the ligation product into a competent E.coli Top10 by a calcium chloride method, selecting transformants for colony PCR and double enzyme digestion identification, selecting 2-3 positive transformants for further verification by sequencing, and successfully obtaining a pET29a-iolX recombinant vector as shown by a sequencing result.
The plasmid map of pET29a-iolX is shown in FIG. 3B.
(3) Construction of pETDuet-iolG-iolX
The pETDuet-iolG plasmid and the iolX gene containing two enzyme cutting sites obtained by PCR in example 1 were each cut with NdeI/KpnI double enzyme at 37 ℃ and the double cut objective fragment and expression vector were recovered separately and ligated at 22 ℃ for 5 hours under the action of T4 ligase. Transforming the ligation product into a competent E.coli Top10 by a calcium chloride method, selecting transformants for colony PCR and double enzyme digestion identification, selecting 2-3 positive transformants for further verification by sequencing, and successfully obtaining a pETDuet-iolG-iolX recombinant co-expression vector by a sequencing result.
The plasmid map of pETDuet-iolG-iolX is shown in FIG. 3C.
(4) Construction of recombinant engineering bacteria
The constructed recombinant plasmids pETDuet-iolG, pET29a-iolX and pETDuet-iolG-iolX are transformed into host bacteria BL21(DE3) by a calcium chloride method respectively, LB test tube is cultured overnight, plasmids are extracted by a plasmid extraction kit, and the correct clone BL21(DE3)/pETDuet-iolG, BL21(DE3)/pET29a-iolX and BL21(DE3)/pETDuet-iolG-iolX are preserved.
EXAMPLE 3 preparation of Whole cells of recombinant engineered bacteria
Recombinant engineered bacteria BL21(DE3)/pETDuet-iolG, BL21(DE3)/pET29a-iolX and BL21(DE3)/pETDuet-iolG-iolX were respectively picked up and inoculated into LB medium containing ampicillin, and cultured overnight with shaking at 37 ℃. The culture was inoculated in 1% of LB medium containing ampicillin freshly, and shake-cultured at 37 ℃ to OD6000.6 to 0.8, the cells were induced overnight at 18 ℃ with a final concentration of 0.1mM IPTG, centrifuged at 5500rpm for 10min, and the supernatant was discarded to obtain whole cells expressing a thermotolerant myo-inositol dehydrogenase, whole cells expressing a thermotolerant scyllo-inositol dehydrogenase, and whole cells co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase.
Example 4 Whole-cell catalysis of myoinositol preparation of scyllo-inositol
The whole cells co-expressing the thermostable myo-inositol dehydrogenase and the thermostable scyllo-inositol dehydrogenase prepared in example 3 were washed 1 time with 0.9% NaCl, centrifuged at 5500rpm for 10min, the supernatant was discarded, 20mM sodium phosphate buffer (pH7.0) was added to the pellet, and the cells were resuspended to OD600About 100. The resuspended cells were heat treated at 65 deg.C, 70 deg.C and 75 deg.C for 20 min.
In a 5mL reaction system, myoinositol at a final concentration of 20g/L, a 20mM sodium phosphate buffer solution (pH7.0), and whole cells heat-treated under different conditions were added to make OD600Whole cells without heat treatment were used as a control at around 20. Shaking the mixture at 55 deg.C and 150rpm in water bath for 6h, and sampling for High Performance Liquid Chromatography (HPLC) analysis. The HPLC detection conditions were as follows: the chromatographic column is Wakopak Wakosil 5NH2(ii) a The mobile phase is acetonitrile/water (v: v, 80: 20); the flow rate is 2 mL/min; the column temperature was 40 ℃; the detector is a differential refraction detector; the amount of sample was 10. mu.L. The liquid chromatogram of myoinositol and scyllo-inositol is shown in FIG. 4.
FIG. 5 shows the production of scyllo-inositol from whole cells heat-treated under different conditions. The results show that when whole cells heat-treated at 70 ℃ for 20min were used as the catalyst, the yield of scyllo-inositol could reach 6.2 g/L.
Example 5 Whole cell catalysis of myo-inositol preparation of scyllo-inositol
The whole cells co-expressing the thermostable myo-inositol dehydrogenase and the thermostable scyllo-inositol dehydrogenase prepared in example 3 were washed 1 time with 0.9% NaCl, centrifuged at 5500rpm for 10min, the supernatant was discarded, 20mM sodium phosphate buffer (pH7.0) was added to the pellet, and the cells were resuspended to OD600About 100. The resuspended cells were heat treated at 70 ℃ for 20 min.
In a 5mL reaction system, myoinositol at a final concentration of 20g/L, 20mM sodium phosphate buffer (pH7.0), and the whole cells heat-treated as described above were added to make OD600About 20. Shaking in water bath at 55 deg.C, 60 deg.C, 65 deg.C, 70 deg.C and 150rpm for 6h, sampling, and analyzing by HPLC. HPLC detection conditions were the same as in example 4.
Figure 6 shows the preparation of scyllo-inositol at different temperatures. The results show that the yield of scyllo-inositol can reach 6.4g/L after the reaction is carried out for 6h at 60 ℃.
Example 6 Whole-cell catalysis of myoinositol preparation of scyllo-inositol
Whole cells were heat treated in the manner described in example 5. In a 5mL reaction system, myoinositol was added to a final concentration of 130g/L, a 20mM sodium phosphate buffer (pH7.0), and the whole cells heat-treated as described above to OD600About 20. The reaction was carried out at 60 ℃ and a water bath of 150rpm for 24h with shaking and samples were taken for HPLC analysis. HPLC detection conditions were the same as in example 4.
The results showed that the content of scyllo-inositol was 50.5 g/L.
Example 7 Whole cell catalysis of myoinositol preparation of scyllo-inositol
Whole cells were heat treated in the manner described in example 5. In a 5mL reaction system, myoinositol was added to a final concentration of 180g/L, a 20mM sodium phosphate buffer (pH7.0), and the whole cells heat-treated as described above to OD600About 20. The reaction was carried out at 60 ℃ and a water bath of 150rpm for 24h with shaking and samples were taken for HPLC analysis. HPLC detection conditions were the same as in example 4.
The results showed that the content of scyllo-inositol was 74.5 g/L.
Example 8 Whole cell catalysis of myoinositol preparation of scyllo-inositol
Whole cells were heat treated in the manner described in example 5. In a 5mL reaction system, myoinositol was added to a final concentration of 250g/L, a 20mM sodium phosphate buffer (pH7.0), and the whole cells heat-treated as described above to OD600About 40. The reaction was carried out at 60 ℃ and a water bath of 150rpm for 24h with shaking and samples were taken for HPLC analysis. HPLC detection conditions were the same as in example 4.
The results showed that the content of scyllo-inositol was 105 g/L.
Example 9 preparation of scyllo-inositol from myoinositol by catalysis of cell lysate
The whole cells co-expressing the thermostable myo-inositol dehydrogenase and the thermostable scyllo-inositol dehydrogenase prepared in example 3 were washed 1 time with 0.9% NaCl, centrifuged at 5500rpm for 10min, the supernatant was discarded, 20mM sodium phosphate buffer (pH7.0) was added to the pellet, and the cells were resuspended to OD600About 100. The resuspended cells were homogenized under high pressure. Cell lysates co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase were obtained by centrifugation at 8000rpm at 4 ℃.
In 5mL of the reaction system, myoinositol was added to a final concentration of 250g/L, 20mM sodium phosphate buffer (pH7.0), and 90% (cell lysate: reaction solution, v/v) of the OD600Approximately 100 total cell lysates. The reaction was carried out at 60 ℃ and a water bath of 150rpm for 24h with shaking and samples were taken for HPLC analysis. HPLC detection conditions were the same as in example 4.
The results showed that the yield of scyllo-inositol was 42%.
Example 10 preparation of scyllo-inositol from myoinositol catalyzed by cell lysate
The whole cells expressing the thermostable myo-inositol dehydrogenase prepared in example 3 and the whole cells expressing the thermostable scyllo-inositol dehydrogenase were washed 1 time with 0.9% NaCl, centrifuged at 5500rpm for 10min, the supernatant was discarded, and 20mM sodium phosphate buffer (pH7.0) was added to each of the precipitates to resuspend the cells to OD600About 100. Respectively homogenizing the resuspended thallus under high pressure, centrifuging at 4 deg.C and 8000rpm to obtain cell lysate expressing thermostable myoinositol dehydrogenase and thermostable shark expressing the myoinositol dehydrogenaseCell lysate of inositol dehydrogenase.
To a 5mL reaction system, myoinositol was added at a final concentration of 250g/L, 20mM sodium phosphate buffer (pH7.0), and 90% (cell lysate: reaction solution, v: v) of the OD600The ratio of the cell lysate expressing a thermostable myo-inositol dehydrogenase to the cell lysate expressing a thermostable scyllo-inositol dehydrogenase added is 1: 1. The reaction was carried out at 60 ℃ and a water bath of 150rpm for 24h with shaking and samples were taken for HPLC analysis. HPLC detection conditions were the same as in example 4.
The results showed that the yield of scyllo-inositol was 42%.
Claims (10)
1. A method for preparing scyllo-inositol, comprising the steps of:
(1) constructing engineering bacteria for co-expressing thermotolerant myo-inositol dehydrogenase and thermotolerant scyllo-inositol dehydrogenase and/or engineering bacteria for respectively expressing the thermotolerant myo-inositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase;
(2) fermenting the engineering bacteria constructed in the step (1) to obtain whole cells;
(3) performing cell membrane permeability treatment and/or disruption on the whole cells obtained in the step (2) to obtain permeable whole cells and/or lysate;
(4) utilizing the whole cell obtained in step (3) to co-express a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a mixture of whole cells expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a lysate of whole cells co-expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a mixture of a lysate of whole cells expressing a thermomycent myo-inositol dehydrogenase and a lysate of whole cells expressing a thermovent scyllo-inositol dehydrogenase, and/or a mixed lysate of whole cells co-expressing a thermomycent myo-inositol dehydrogenase and a thermovent scyllo-inositol dehydrogenase, a lysate of whole cells expressing a thermomycent myo-inositol dehydrogenase and a lysate of whole cells expressing a thermovent scyllo-inositol dehydrogenase The compounds catalyze myo-inositol to produce scyllo-inositol.
2. The method of claim 1, wherein the engineered bacterium comprises a vector co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase, or comprises both a vector expressing a thermotolerant myo-inositol dehydrogenase and a vector expressing a thermotolerant scyllo-inositol dehydrogenase, or comprises a vector expressing a thermotolerant myo-inositol dehydrogenase, or comprises a vector expressing a thermotolerant scyllo-inositol dehydrogenase.
Preferably, the thermotolerant myo-inositol dehydrogenase is an enzyme having a function of oxidizing myo-inositol to myo-inositol monoketone at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermotolerant myo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermotolerant myo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermotolerant myo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Thermotoga maritima (Thermotoga maritima), Pseudothermoga thermomarum.
Preferably, the thermostable scyllo-inositol dehydrogenase is an enzyme having a function of reducing myoinositol monoketone to scyllo-inositol at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermostable scyllo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermostable scyllo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermostable scyllo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Geobacillus thermophiliovorans, Thermotoga maritima (Thermotoga maritima).
Preferably, the vector co-expressing the thermotolerant myoinositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase comprises a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant scyllo-inositol dehydrogenase gene and a second terminator, or comprises a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant myoinositol dehydrogenase gene and a second terminator, or comprises a promoter, a thermotolerant scyllo-inositol dehydrogenase gene, a thermotolerant myoinositol dehydrogenase gene and a terminator, or comprises a promoter, a thermotolerant myoinositol dehydrogenase gene, a thermotolerant scyllo-inositol dehydrogenase gene and a terminator; the vector for expressing the heat-resistant myoinositol dehydrogenase comprises a promoter, a heat-resistant myoinositol dehydrogenase gene and a terminator; the carrier for expressing the heat-resistant scyllo-inositol dehydrogenase comprises a promoter, a heat-resistant scyllo-inositol dehydrogenase gene and a terminator.
Preferably, the promoter, the first promoter and/or the second promoter include, but are not limited to, T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, and the like. Most preferably, the promoter, the first promoter, the second promoter are independently from each other the T7 promoter.
Preferably, the terminator, first terminator and/or second terminator include, but are not limited to, the T7 terminator, the rrnB T1 terminator, the rrnB T2 terminator and the like. Most preferably, the terminator, the first terminator, the second terminator are independently from each other the T7 terminator.
Preferably, the vector is pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, etc., most preferably pETDuet-1 or pET-29a (+).
Preferably, the host bacteria for preparing the engineering bacteria are escherichia coli, pichia pastoris, saccharomyces cerevisiae, bacillus subtilis and the like, and most preferably escherichia coli BL21(DE 3).
3. The method according to claim 1 or 2, wherein the cell membrane permeability treatment comprises but is not limited to heat treatment, addition of organic solvents and/or addition of surfactants.
Preferably, the heat treatment temperature is 45-95 ℃; further preferably, the heat treatment temperature is 55-90 ℃; more preferably, the heat treatment temperature is 60-80 ℃; most preferably, the heat treatment temperature is 70 ℃.
Preferably, the heat treatment time is 1-40 min; further preferably, the heat treatment time is 5-30 min; more preferably, the heat treatment time is 10-25 min; most preferably, the heat treatment time is 20 min.
Preferably, the cell concentration at the time of the heat treatment is OD60010-300; further preferably, the cell concentration is OD60020-200; more preferably, the cell concentration is OD60050-150; most preferably, the cell concentration is OD600＝100。
Preferably, the heat treatment can be carried out in a buffer-free system or a buffer system; more preferably, the heat treatment is performed in a buffer system, and the buffer may be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, or the like. Among them, phosphate buffer solutions such as sodium phosphate buffer solution, potassium phosphate buffer solution, and the like.
4. The method of any one of claims 1 to 3, wherein the substrate myo-inositol is present in a concentration of 1 to 400g/L in the reaction system for producing scyllo-inositol by catalyzing myo-inositol with permeable whole cells or a mixture of permeable whole cells, and the amount of permeable whole cells or a mixture of permeable whole cells added is OD6001-100; more preferably, the concentration of myoinositol as substrate is 100-350g/L and the amount of permeable whole cells or mixture of permeable whole cells added is OD60010-50; most preferably, the substrate myoinositol is present at a concentration of 250g/L and the permeable whole cells or mixture of permeable whole cells are added in an amount OD600＝20-40。
Preferably, the ratio of permeable whole cells expressing a thermotolerant myo-inositol dehydrogenase to permeable whole cells expressing a thermotolerant scyllo-inositol dehydrogenase in the mixture of permeable whole cells is 0.1:1 to 10: 1; more preferably from 0.5:1 to 5: 1; most preferably 1: 1.
5. The method of any one of claims 1 to 3, wherein the substrate myo-inositol is present in a concentration of 1 to 400g/L in the reaction system for producing scyllo-inositol by catalyzing myo-inositol with a cell lysate or a mixture of cell lysates using whole cell OD600The adding amount of the cracking solution is 5 to 95 percent of the total volume of the reaction solution when the reaction solution is 10 to 100 percent; more preferably, the concentration of myoinositol as substrate is 100-350g/L and the cell lysate or mixture of cell lysates is the whole cell OD600The adding amount of the cracking solution is 50 to 90 percent of the total volume of the reaction solution when the reaction solution is 40 to 150 hours; most preferably, the concentration of myoinositol as substrate is 250g/L and the cell lysate or mixture of cell lysates is whole cell OD600The amount of the lysate added was 90% of the total volume of the reaction solution, when the amount of the lysate was 100%.
Preferably, the ratio of whole cells used in whole cell lysates expressing a thermotolerant myo-inositol dehydrogenase to whole cells used in whole cell lysates expressing a thermotolerant scyllo-inositol dehydrogenase in the mixture of whole cell lysates is 0.1:1-10: 1; more preferably from 0.5:1 to 5: 1; most preferably 1: 1.
6. The process according to any one of claims 1 to 5, characterized in that the conditions of the catalytic reaction are: reacting at pH 6.0-8.0 and 50-80 deg.C for 0.5-72 hr; more preferably at pH 6.5-7.5, at 55-75 deg.C for 3-48 h; most preferably at pH7.0, 60-65 ℃ for 6-24 h.
Preferably, the catalytic reaction can be carried out in a buffer-free system or a buffer system; preferably in a buffer system, which may be HEPES buffer, phosphate buffer, Tris buffer, acetate buffer, etc. Among them, phosphate buffer solutions such as sodium phosphate buffer solution, potassium phosphate buffer solution, and the like.
7. A vector for co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase.
Preferably, the thermotolerant myo-inositol dehydrogenase is an enzyme having a function of oxidizing myo-inositol to myo-inositol monoketone at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermotolerant myo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermotolerant myo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermotolerant myo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Thermotoga maritima (Thermotoga maritima), Pseudothermoga thermomarum.
Preferably, the thermostable scyllo-inositol dehydrogenase is an enzyme having a function of reducing myoinositol monoketone to scyllo-inositol at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermostable scyllo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermostable scyllo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermostable scyllo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Geobacillus thermophiliovorans, Thermotoga maritima (Thermotoga maritima).
Preferably, the vector co-expressing the thermotolerant myoinositol dehydrogenase and the thermotolerant scyllo-inositol dehydrogenase comprises a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant scyllo-inositol dehydrogenase gene and a second terminator, or comprises a first promoter, a thermotolerant myoinositol dehydrogenase gene, a first terminator, a second promoter, a thermotolerant myoinositol dehydrogenase gene and a second terminator, or comprises a promoter, a thermotolerant scyllo-inositol dehydrogenase gene, a thermotolerant myoinositol dehydrogenase gene and a terminator, or comprises a promoter, a thermotolerant myoinositol dehydrogenase gene, a thermotolerant scyllo-inositol dehydrogenase gene and a terminator.
Preferably, the first promoter and/or the second promoter include, but are not limited to, T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, and the like. Most preferably, the first promoter and the second promoter are independent of each other T7 promoter.
Preferably, the first terminator and/or the second terminator include, but are not limited to, a T7 terminator, a rrnB T1 terminator, a rrnB T2 terminator, and the like. Most preferably, the first terminator and the second terminator are independent of each other, and are T7 terminators.
Preferably, the vector is pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, etc., most preferably pETDuet-1 or pET-29a (+).
8. A vector for expressing a thermotolerant myo-inositol dehydrogenase.
Preferably, the thermotolerant myo-inositol dehydrogenase is an enzyme having a function of oxidizing myo-inositol to myo-inositol monoketone at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermotolerant myo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermotolerant myo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermotolerant myo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Thermotoga maritima (Thermotoga maritima), Pseudothermoga thermomarum.
Preferably, the vector for expressing the thermotolerant myo-inositol dehydrogenase includes a promoter, a thermotolerant myo-inositol dehydrogenase gene, and a terminator.
Preferably, the promoter includes, but is not limited to, T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, and the like. Most preferably, the promoter is the T7 promoter.
Preferably, the terminator includes, but is not limited to, a T7 terminator, a rrnB T1 terminator, a rrnB T2 terminator, and the like. Most preferably, the terminator is the T7 terminator.
Preferably, the vector is pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, etc., most preferably pETDuet-1 or pET-29a (+).
9. A vector for expressing a thermostable scyllo-inositol dehydrogenase.
Preferably, the thermostable scyllo-inositol dehydrogenase is an enzyme having a function of reducing myoinositol monoketone to scyllo-inositol at 50 ℃ or higher, 55 ℃ or higher, 60 ℃ or higher, 65 ℃ or higher, 70 ℃ or higher, 75 ℃ or higher, or 80 ℃ or higher. Further preferably, the thermostable scyllo-inositol dehydrogenase is derived from a thermophilic microorganism or the amino acid sequence of the thermostable scyllo-inositol dehydrogenase is at least 70%, preferably at least 80%, more preferably at least 90%, most preferably at least 95% identical to a thermostable scyllo-inositol dehydrogenase derived from a thermophilic microorganism. More preferably, the thermophilic microorganism is selected from Geobacillus thermophilus (Geobacillus kaustophilus), Geobacillus stearothermophilus (Geobacillus stearothermophilus), Geobacillus thermophiliovorans, Thermotoga maritima (Thermotoga maritima).
Preferably, the vector for expressing the heat-resistant scyllo-inositol dehydrogenase comprises a promoter, a heat-resistant scyllo-inositol dehydrogenase gene and a terminator.
Preferably, the promoter includes, but is not limited to, T7 promoter, lac promoter, tac promoter, trc promoter, PR promoter, and the like. Most preferably, the promoter is the T7 promoter.
Preferably, the terminator includes, but is not limited to, a T7 terminator, a rrnB T1 terminator, a rrnB T2 terminator, and the like. Most preferably, the terminator is the T7 terminator.
Preferably, the vector is pET series, pGEX series, pACYCDuet-1, pRSFDuet-1, etc., most preferably pETDuet-1 or pET-29a (+).
10. An engineering bacterium for co-expressing a thermotolerant myo-inositol dehydrogenase and a thermotolerant scyllo-inositol dehydrogenase, an engineering bacterium for expressing the thermotolerant myo-inositol dehydrogenase or an engineering bacterium for expressing the thermotolerant scyllo-inositol dehydrogenase.
Preferably, the engineered bacterium comprises the vector of claim 7, 8 or 9.
Preferably, the host bacteria for preparing the engineering bacteria are escherichia coli, pichia pastoris, saccharomyces cerevisiae, bacillus subtilis and the like, and most preferably escherichia coli BL21(DE 3).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810973696.4A CN110857444B (en) | 2018-08-24 | 2018-08-24 | Preparation method of scyllo-inositol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810973696.4A CN110857444B (en) | 2018-08-24 | 2018-08-24 | Preparation method of scyllo-inositol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110857444A true CN110857444A (en) | 2020-03-03 |
| CN110857444B CN110857444B (en) | 2022-01-25 |
Family
ID=69636267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810973696.4A Active CN110857444B (en) | 2018-08-24 | 2018-08-24 | Preparation method of scyllo-inositol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110857444B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114717277A (en) * | 2022-04-11 | 2022-07-08 | 中国科学院天津工业生物技术研究所 | Nano cellulose and preparation method and application thereof |
| CN117844665A (en) * | 2023-12-14 | 2024-04-09 | 湖北大学 | Recombinant yeast engineering strain, preparation thereof and application thereof in degradation of PET plastic |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1867676A (en) * | 2003-10-14 | 2006-11-22 | 北兴化学工业株式会社 | Process for producing scyllo-inositol |
| CN102869639A (en) * | 2010-02-15 | 2013-01-09 | Abbvie公司 | Process for the preparation of scyllo-inositol |
| CN104245950A (en) * | 2012-02-02 | 2014-12-24 | 旭化成化学株式会社 | Method for producing scyllo-inositol |
-
2018
- 2018-08-24 CN CN201810973696.4A patent/CN110857444B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1867676A (en) * | 2003-10-14 | 2006-11-22 | 北兴化学工业株式会社 | Process for producing scyllo-inositol |
| CN102869639A (en) * | 2010-02-15 | 2013-01-09 | Abbvie公司 | Process for the preparation of scyllo-inositol |
| CN104245950A (en) * | 2012-02-02 | 2014-12-24 | 旭化成化学株式会社 | Method for producing scyllo-inositol |
Non-Patent Citations (1)
| Title |
|---|
| YAMAOKA MASARU等: "A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer"s disease", 《MICROBIAL CELL FACTORIES》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114717277A (en) * | 2022-04-11 | 2022-07-08 | 中国科学院天津工业生物技术研究所 | Nano cellulose and preparation method and application thereof |
| CN114717277B (en) * | 2022-04-11 | 2024-03-12 | 中国科学院天津工业生物技术研究所 | Nanocellulose and preparation method and application thereof |
| CN117844665A (en) * | 2023-12-14 | 2024-04-09 | 湖北大学 | Recombinant yeast engineering strain, preparation thereof and application thereof in degradation of PET plastic |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110857444B (en) | 2022-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104099379B (en) | A kind of method and application of the biosynthesis tyrosol in Escherichia coli | |
| US20210254109A1 (en) | D-Glucaric Acid Producing Bacterium, and Method for Manufacturing D-Glucaric Acid | |
| EP3561049A1 (en) | Genetically engineered bacterium of coexpressing cyclohexanone monooxygenase and isopropanol dehydrogenase and use thereof | |
| CN108467860B (en) | Method for high yield of gamma-aminobutyric acid | |
| CN108753808B (en) | Recombinant expression vector, recombinant expression host and method for synthesizing adenosine triphosphate by using recombinant expression vector | |
| US10294479B2 (en) | Candida carbonyl reductase and method for preparing (R)-lipoic acid precursor | |
| US9663799B2 (en) | Hydrocarbon synthase gene and use thereof | |
| CN109706189B (en) | Preparation method of D-chiro-inositol | |
| CN109468291B (en) | Carbonyl reductase EbSDR8 mutant and construction method and application thereof | |
| CN105734092B (en) | A kind of method that enzyme process prepares D-Tag | |
| CN103898177B (en) | Prepare the method for high chiral purity (R)-3-piperidine alcohols and derivative thereof | |
| CN110857444B (en) | Preparation method of scyllo-inositol | |
| CN112126610A (en) | Engineering bacterium for producing hydroxytyrosol | |
| CN106884029A (en) | The method of enzyme' s catalysis niacinamide cytimidine dinucleotides | |
| CN111454918B (en) | Enol reductase mutant and application thereof in preparation of (R) -citronellal | |
| CN110938606B (en) | HpaBC gene, mutant and application thereof | |
| CN113913399B (en) | Ketopantolactone reductase from Candida maltosa Xu316 | |
| CN116355820A (en) | Engineering strain for high yield of ergothioneine and method for producing ergothioneine by same | |
| CN114085820B (en) | Ketopantolactone reductase from Candida viswanathii | |
| Radoš et al. | Stereospecificity of Corynebacterium glutamicum 2, 3-butanediol dehydrogenase and implications for the stereochemical purity of bioproduced 2, 3-butanediol | |
| CN109897872B (en) | Enzymatic preparation of (2S, 3S) -N-t-butoxycarbonyl-3-amino-1-chloro-2-hydroxy-4-phenylbutane | |
| CN101186924A (en) | Gene engineering bacterium for catalyzing citral to produce citronellal and construction method thereof | |
| CN114350630A (en) | L-pantolactone dehydrogenase, mutant and application thereof | |
| CN114426978A (en) | Recombinant engineering bacterium and construction method and application thereof | |
| CN112226420A (en) | Nitroreductase mutant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Yiheng Inventor after: You Chun Inventor after: Li Yuan Inventor after: Liu Shan Inventor before: You Chun Inventor before: Li Yuan Inventor before: Liu Shan |